Skip to main content
x

Recent articles

A new challenger in target degradation

Ascentage hopes to become a new force in BTK.

CCR8 promise and peril

Pivotal trials and novel combinations have started, but four programmes seem to have been discontinued.

EAU 2026 – J&J strengthens its bladder hand

Erda-iDRS maintains its promise in FGFR mutants, but adverse events could give pause.

CytomX looks good enough in colorectal cancer

Varseta-M efficacy wanes, but more than justifies a pivotal trial.

AbbVie and RemeGen’s bispecific goes pivotal

Chinese trials in first-line NSCLC and colorectal cancer are imminent.

Mid-stage promise turns to pivotal bust for Immutep

Tacti-004 is terminated for futility, and Immutep crashes 89%.